News
Abzena appoints Matthew LeClair as SVP and Site Head of San Diego Operations
Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Matthew LeClair as Senior Vice President (SVP) and Site Head of its San Diego Operations.
With...
News
Biocair Expands US Presence And Capacity
With the expansion of two of Biocair’s North American facilities, the company’s offerings in the US have increased substantially.
The Philadelphia office has doubled in size, with a state-of-the-art cryogenic filling station to further support cell and gene therapy...
News
Pharmapack Moves to May 2021
Pharmapack Europe, organised by Informa Markets, moves to May 2021 (19-20) to provide attendees, exhibitors and the pharma packaging community the best season and format. The decision follows a careful review with key stakeholders, with the exhibition continuing at...
News
FDA Grants Emergency Use Authorization for Eli Lilly, Sandia National Labs Coronavirus PCR Tests
The US FDA granted separate Emergency Use Authorizations for PCR-based SARS-CoV-2 tests developed by Eli Lilly and Sandia National Laboratories.
The Lilly SARS-CoV-2 Assay is designed to detect the virus' nucleocapsid gene in nasopharyngeal, oropharyngeal, anterior nasal, and midturbinate swabs,...
News
European Union signs Remdesivir deal with Gilead
The European Union's executive said that it has signed a contract with Gilead for its COVID-19 medicine remdesivir that would cover 30,000 patients in the bloc from early August.
"The Commission signed a contract with the pharmaceutical company Gilead for...
News
AstraZeneca’s Calquence Receives Positive CHMP Opinion For Chronic Blood Cancer
AstraZeneca’s Calquence has been recommended for marketing authorisation in the EU for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.
The Committee for Medicinal Products for Human Use (CHMP) of...
News
US to invest $472 million more in Moderna to speed up vaccine process
Moderna has unveiled a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
